The CD38-targeting biologic daratumumab has modest inhibitory activity against CD38 cyclase activity and enhances CD38 hydrolase activity.69 In addition, CD38 mAbs may also mask regions of the CD38 epitope that are necessary for important CD38 receptor functions that promote NK cell interferon secretion and tumor cell cytotoxicity. Here, CD38 is linked to neoplasm.